10 Feb 2021
A commonly used asthma treatment appears to reduce the need for hospitalizations as well as recovery time for COVID-19 patients if it’s given within seven days of symptoms appearing, researchers at the University of Oxford said.
The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca.
The 28-day study of 146 patients suggested that inhaled budesonide reduced the risk of urgent care or hospitalization by 90% compared with the usual care.